202 related articles for article (PubMed ID: 9354443)
1. Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH.
Gabr A; Kuin A; Aalders M; El-Gawly H; Smets LA
Cancer Res; 1997 Nov; 57(21):4811-6. PubMed ID: 9354443
[TBL] [Abstract][Full Text] [Related]
2. Camptothecin analogues with enhanced antitumor activity at acidic pH.
Adams DJ; Dewhirst MW; Flowers JL; Gamcsik MP; Colvin OM; Manikumar G; Wani MC; Wall ME
Cancer Chemother Pharmacol; 2000; 46(4):263-71. PubMed ID: 11052623
[TBL] [Abstract][Full Text] [Related]
3. The activity of camptothecin analogues is enhanced in histocultures of human tumors and human tumor xenografts by modulation of extracellular pH.
Flowers JL; Hoffman RM; Driscoll TA; Wall ME; Wani MC; Manikumar G; Friedman HS; Dewhirst M; Colvin OM; Adams DJ
Cancer Chemother Pharmacol; 2003 Sep; 52(3):253-61. PubMed ID: 12783198
[TBL] [Abstract][Full Text] [Related]
4. Caffeine prevents apoptosis and cell cycle effects induced by camptothecin or topotecan in HL-60 cells.
Traganos F; Kapuscinski J; Gong J; Ardelt B; Darzynkiewicz RJ; Darzynkiewicz Z
Cancer Res; 1993 Oct; 53(19):4613-8. PubMed ID: 8402636
[TBL] [Abstract][Full Text] [Related]
5. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue.
Hendricks CB; Rowinsky EK; Grochow LB; Donehower RC; Kaufmann SH
Cancer Res; 1992 Apr; 52(8):2268-78. PubMed ID: 1348448
[TBL] [Abstract][Full Text] [Related]
6. Differential effects of the poly (ADP-ribose) polymerase (PARP) inhibitor NU1025 on topoisomerase I and II inhibitor cytotoxicity in L1210 cells in vitro.
Bowman KJ; Newell DR; Calvert AH; Curtin NJ
Br J Cancer; 2001 Jan; 84(1):106-12. PubMed ID: 11139322
[TBL] [Abstract][Full Text] [Related]
7. A phase I and translational study of sequential administration of the topoisomerase I and II inhibitors topotecan and etoposide.
Hammond LA; Eckardt JR; Ganapathi R; Burris HA; Rodriguez GA; Eckhardt SG; Rothenberg ML; Weiss GR; Kuhn JG; Hodges S; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 1998 Jun; 4(6):1459-67. PubMed ID: 9626463
[TBL] [Abstract][Full Text] [Related]
8. Topotecan-induced alterations in the amount and stability of human DNA topoisomerase I in solid tumor cell lines.
Devy J; Wargnier R; Pluot M; Nabiev I; Sukhanova A
Anticancer Res; 2004; 24(3a):1745-51. PubMed ID: 15274350
[TBL] [Abstract][Full Text] [Related]
9. Subcellular localization of the camptothecin analogues, topotecan and gimatecan.
Croce AC; Bottiroli G; Supino R; Favini E; Zuco V; Zunino F
Biochem Pharmacol; 2004 Mar; 67(6):1035-45. PubMed ID: 15006540
[TBL] [Abstract][Full Text] [Related]
10. The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.
Smith LM; Willmore E; Austin CA; Curtin NJ
Clin Cancer Res; 2005 Dec; 11(23):8449-57. PubMed ID: 16322308
[TBL] [Abstract][Full Text] [Related]
11. Homocamptothecins: synthesis and antitumor activity of novel E-ring-modified camptothecin analogues.
Lavergne O; Lesueur-Ginot L; Pla Rodas F; Kasprzyk PG; Pommier J; Demarquay D; Prévost G; Ulibarri G; Rolland A; Schiano-Liberatore AM; Harnett J; Pons D; Camara J; Bigg DC
J Med Chem; 1998 Dec; 41(27):5410-9. PubMed ID: 9876111
[TBL] [Abstract][Full Text] [Related]
12. Effective schedules of exposure of medulloblastoma and rhabdomyosarcoma xenografts to topotecan correlate with in vitro assays.
Pawlik CA; Houghton PJ; Stewart CF; Cheshire PJ; Richmond LB; Danks MK
Clin Cancer Res; 1998 Aug; 4(8):1995-2002. PubMed ID: 9717830
[TBL] [Abstract][Full Text] [Related]
13. Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).
Kuin A; Aalders M; Lamfers M; van Zuidam DJ; Essers M; Beijnen JH; Smets LA
Br J Cancer; 1999 Feb; 79(5-6):793-801. PubMed ID: 10070871
[TBL] [Abstract][Full Text] [Related]
14. A novel camptothecin analog with enhanced antitumor activity.
Yount G; Yang Y; Wong B; Wang HJ; Yang LX
Anticancer Res; 2007; 27(5A):3173-8. PubMed ID: 17970058
[TBL] [Abstract][Full Text] [Related]
15. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments.
Jensen PB; Sørensen BS; Sehested M; Grue P; Demant EJ; Hansen HH
Cancer Res; 1994 Jun; 54(11):2959-63. PubMed ID: 8187081
[TBL] [Abstract][Full Text] [Related]
16. Comparative brain tissue distribution of camptothecin and topotecan in the rat.
El-Gizawy SA; Hedaya MA
Cancer Chemother Pharmacol; 1999; 43(5):364-70. PubMed ID: 10100590
[TBL] [Abstract][Full Text] [Related]
17. Antiangiogenic potential of camptothecin and topotecan.
Clements MK; Jones CB; Cumming M; Daoud SS
Cancer Chemother Pharmacol; 1999; 44(5):411-6. PubMed ID: 10501915
[TBL] [Abstract][Full Text] [Related]
18. The current status of camptothecin analogues as antitumor agents.
Slichenmyer WJ; Rowinsky EK; Donehower RC; Kaufmann SH
J Natl Cancer Inst; 1993 Feb; 85(4):271-91. PubMed ID: 8381186
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
20. Topotecan lactone selectively binds to double- and single-stranded DNA in the absence of topoisomerase I.
Yao S; Murali D; Seetharamulu P; Haridas K; Petluru PN; Reddy DG; Hausheer FH
Cancer Res; 1998 Sep; 58(17):3782-6. PubMed ID: 9731484
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
